Literature DB >> 3568269

Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.

D Roberts, T Lee, E Parganas, L Wiggins, J Yalowich, R Ashmun.   

Abstract

Resistance to teniposide (VM-26) by VM-26 selected resistant L1210 cells in culture was attributed to alterations in the flux of VM-26 across the plasma membrane and to functions of homogeneously staining regions that appeared on one or more chromosomes. In the present study, electrophoresis of membrane-cytosol fractions of these resistant sublines demonstrated a protein band, Mr 22 kd, that was not evident in similar fractions of drug-sensitive L1210 cells or three revertant sublines. The distribution of this protein among various cellular fractions could be altered by manipulation of the concentration of calcium ions. A representative subline, LIa5 microM, was observed to have vesicles that reacted with Sudan black B stain, an indication of altered lipid metabolism. The LIa5 microM subline was cross-resistant to etoposide, vincristine, doxorubicin, amsacrine, and actinomycin D. Concentrations of VM-26 that inhibited cell division to the same extent caused an accumulation of fewer cells in the G2 stage of cell division in LIa5 microM cultures than in L1210 cultures. These observations indicate that the LIa5 microM subline expressed multiple drug resistance, as well as changes in the expression of cytotoxicity to VM-26.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3568269     DOI: 10.1007/bf00254563

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  59 in total

1.  Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells.

Authors:  J D Loike; S B Horwitz
Journal:  Biochemistry       Date:  1976-12-14       Impact factor: 3.162

2.  VM26-induced changes in hepatic intermediary metabolism of mice.

Authors:  M Hacker; D Roberts
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.

Authors:  T Lee; D Roberts
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

5.  Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.

Authors:  R S Gupta
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

6.  Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.

Authors:  T Skovsgaard
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

7.  Membrane alterations associated with progressive adriamycin resistance.

Authors:  C Wheeler; R Rader; D Kessel
Journal:  Biochem Pharmacol       Date:  1982-08-15       Impact factor: 5.858

8.  4'-Demethylepipodophyllotoxin-beta-D-glucoside: a new podophyllotoxin derivative with VM-26-like and VP-16-213-like activities.

Authors:  R S Gupta; B Singh
Journal:  J Natl Cancer Inst       Date:  1984-07       Impact factor: 13.506

9.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.

Authors:  D R Bell; J H Gerlach; N Kartner; R N Buick; V Ling
Journal:  J Clin Oncol       Date:  1985-03       Impact factor: 44.544

10.  5'-Nucleotidase activity and arachidonate metabolism in doxorubicin sensitive and resistant P388 cells.

Authors:  A Ramu; D Glaubiger; P Soprey; G H Reaman; N Feuerstein
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

View more
  3 in total

1.  Association of sorcin with drug resistance in L1210 cells.

Authors:  D Roberts; M B Meyers; J L Biedler; L G Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.

Authors:  D W Roberts; P D Foglesong; E Parganas; L Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Topoisomerase II in multiple drug resistance.

Authors:  G A Hofmann; M R Mattern
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.